Novobiocin

Generic Name: Novobiocin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₁H_₃₆N_₂O_₁₁

CAS Number: 303-81-1

Unique Ingredient Identifier: 17EC19951N

Background: Novobiocin is an antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189)

Novobiocin sodium, a salt form of novobiocin, was initially approved in September 1964 and was indicated for the treatment of serious infections due to susceptible strains of Staphylococcus aureus when other less toxic antibiotics cannot be used. In 2009, the FDA determined novobiocin sodium was withdrawn from sale for reasons of safety or effectiveness.

Indication: ⑴抗菌谱和青霉素相似，主要用于耐药性金葡菌引起的感染，如肺炎、败血症等，对严重感染疗效较差。易引起细菌耐药性，故宜和其他抗菌药物配伍应用。

⑵由于本品对DNA回旋酶有很好的抑制作用，对多种癌细胞有抑制作用，并能与抗癌药联合应用，逆转抗癌药的耐药性。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Precision Cancer Medicine and Profile at Dana-Farber

Precision cancer medicine tailors treatment to each patient's unique cancer biology, using genetic profiling to target specific abnormalities. Initiatives like Profile at Dana-Farber analyze tumor genetics to guide therapy, aiming for effective treatments with fewer side effects. This approach leverages advancements in genomic research and targeted therapies, including immunotherapy, to improve cancer care.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy